Overview
LNAI market data
Price History
LNAI price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$10.47 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.42 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -4,350.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.21 – $21.20 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $11M.
Company News
Lunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027Benzinga · Aug 4, 2026, 7:31 PM
Lunai Bioworks Files Amended RICO Complaint Expanding Naked Short-Selling Lawsuit; Names 10 Defendants, Including 3 FINRA Registered Broker Dealers, In Connection With An Alleged Coordinated Naked Short Selling Scheme That The Company Says Generated Failures To Deliver On More Than 81% Of Its Outstanding SharesBenzinga · Aug 4, 2026, 1:23 PM
8-K filing — Lunai Bioworks Inc. (LNAI)SEC EDGAR · Jun 17, 2026, 8:32 PM
Lunai Bioworks Regains Nasdaq ComplianceBenzinga · Jun 16, 2026, 8:10 PM
Lunai Bioworks' BioSymetrics And BrainStorm Therapeutics Announce Strategic Collaboration And LOI Integrating AI Discovery, Human Brain Organoid Modeling, And In Vivo Validation To Generate Differentiated Neurology Assets For Pharmaceutical Partnering And DevelopmentBenzinga · May 28, 2026, 1:25 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · May 22, 2026, 1:50 PM
Federal Judge Granted Lunai Bioworks Permission On May 20 To Conduct Expedited Third-Party Discovery To Identify Naked Short Sellers Of Lunai Common Stock Through 2025-2026Benzinga · May 22, 2026, 1:30 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News PendingBenzinga · May 21, 2026, 11:55 PM
Lunai Bioworks Announces 1-For-8 Reverse Stock Split Effective May 22Benzinga · May 20, 2026, 1:25 PM
Lunai Bioworks Inc. - Common Stock Q3 EPS $(0.10), Sales $20.942KBenzinga · May 15, 2026, 10:19 PM